{"id":475274,"date":"2020-03-20T15:52:01","date_gmt":"2020-03-20T15:52:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=475274"},"modified":"2020-03-20T15:52:01","modified_gmt":"2020-03-20T15:52:01","slug":"synovial-sarcoma-market-insights-epidemiology-and-market-forecast-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/synovial-sarcoma-market-insights-epidemiology-and-market-forecast-2030_475274.html","title":{"rendered":"Synovial Sarcoma Market Insights, Epidemiology and Market Forecast 2030"},"content":{"rendered":"
\"Synovial<\/a><\/div>\n
DelveInsight’s “Synovial Sarcoma – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Synovial Sarcoma , historical and forecasted epidemiology as well as the Synovial Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n

(Albany, NY) DelveInsight launched its new report on Synovial Sarcoma Market Insights, Epidemiology and Market Forecast 2030<\/a><\/p>\n

DelveInsight’s “Synovial Sarcoma – Market Insights, Epidemiology, and Market Forecast-2030<\/strong>” report delivers an in-depth understanding of the Synovial Sarcoma , historical and forecasted epidemiology as well as the Synovial Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Key facts from the report:<\/strong>
The Total diagnosed synovial sarcoma incident cases in 7MM were 1777 in 2017, the United States account for highest diagnosed incident cases of synovial sarcoma. In 2017, the United States had 489 diagnosed synovial sarcoma incident cases in 2017.<\/p>\n

Some key benefits of the report:
<\/strong>1. Synovial Sarcoma market report covers a descriptive overview and comprehensive insight of the Synovial Sarcoma epidemiology and Synovial Sarcoma market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Synovial Sarcoma market report provides insights on the current and emerging therapies.
3. Synovial Sarcoma market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Synovial Sarcoma market report offers an edge that will help in developing business strategies by understanding trends moulding and leading the Synovial Sarcoma market.<\/p>\n

\"\"<\/p>\n

Download a free sample report on Synovial Sarcoma<\/strong> @https:\/\/www.delveinsight.com\/sample-request\/synovial-sarcoma-market<\/p>\n

The key players in Synovial Sarcoma market are:<\/strong>
1. Epizyme
2. Adaptimmune
3. Advenchen Laboratories<\/p>\n

The launch of the emerging therapies is expected to significantly impact the Synovial Sarcoma treatment scenario in the upcoming years: –<\/strong><\/p>\n

Drugs covered<\/span><\/strong>
1. Tazemetostat<\/span>
2. ADP-A2M4<\/span>
3. Anlotinib (AL3818)<\/span><\/p>\n

Table of Contents:<\/strong><\/p>\n

1. Key Insights<\/span>
2. Synovial Sarcoma Market Overview at a Glance<\/span>
3. Synovial Sarcoma Disease Background and Overview<\/span>
4. Synovial Sarcoma Epidemiology and Patient Population<\/span>
5. Synovial Sarcoma Country Wise-Epidemiology<\/span>
5.1. United States<\/span>
5.2. EU5 Countries<\/span>
5.3. Germany<\/span>
5.4. France<\/span>
5.5. Italy<\/span>
5.6. Spain<\/span>
5.7. United Kingdom<\/span>
5.8. Japan<\/span>
6. Guidelines for Synovial Sarcoma Treatment\/ Management of Soft-Tissue Sarcoma<\/span>
7. Unmet needs<\/span>
8. Synovial Sarcoma Marketed Drugs<\/span>
8.1. Yondelis (Trabectadin)<\/span>
8.2. Pazopanib: Novartis<\/span>
9. Synovial Sarcoma Emerging drugs<\/span>
9.1. Tazemetostat: Epizyme, Inc.<\/span>
9.2. ADP-A2M4: Adaptimmune<\/span>
9.3. Anlotinib (AL3818): Advenchen Laboratories<\/span>
10. Synovial Sarcoma 7 Major Market Analysis<\/span>
11. The United States Market Outlook<\/span>
11.1.United States Market Size<\/span>
12. EU-5 Countries: Market Outlook<\/span>
12.1.Germany<\/span>
12.2. France<\/span>
12.3. Italy<\/span>
12.4. Spain<\/span>
12.5. The United Kingdom<\/span>
13. Japan: Market Outlook<\/span>
13.1.Japan market Size<\/span>
14. Market Drivers<\/span>
15. Market Barriers<\/span>
16. Appendix<\/span>
17. DelveInsight Capabilities<\/span>
18. Disclaimer<\/span>
19. About DelveInsight<\/span><\/p>\n

Related reports:<\/strong><\/p>\n

Synovial sarcoma (SS) – Epidemiology Forecast to 2030<\/a><\/strong><\/p>\n

Tenosynovial Giant Cell Tumors (TSGCTs) – Market Insights, Epidemiology, and Market Forecast-2030<\/a><\/strong><\/p>\n

Tenosynovial Giant Cell Tumors (TSGCTs) – Epidemiology Forecast to 2030<\/a><\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Anuj Rawat
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +919650213330
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight’s “Synovial Sarcoma – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Synovial Sarcoma , historical and forecasted epidemiology as well as the Synovial Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-475274","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/475274","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=475274"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/475274\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=475274"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=475274"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=475274"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}